Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr raises $90M to rewrite treatment of rare muscle disease
(3h)
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
(4h)
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
(5h)
BioPharma Dive
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
(1h)
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
(4h)
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
(5h)
Endpoints News
Two health insurers give an AI reality check
(2h)
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
(3h)
Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says
(4h)
BioSpace
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
(3h)
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
(4h)
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
(5h)
STAT News
Trump is counting on the health care industry to remake vaccines. They’re pushing back instead
(54m)
Trump says his executive order should restore trust in vaccines. It does the exact opposite
(1h)
How we know that splitting up the MMR vaccine could be dangerous
(3h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
Drug Channels
The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America
(7h)
Informa Connect’s Medicaid Drug Rebate Program Summit
(1d)
A System of Record, or a System of Learning?
(4d)
European Biotechnology Magazine
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3
(1d)
Clinical Development Expert has started
(4d)
Actimed retrieves ALS drug after Faraday collapse
(5d)
Drug Hunter
Rethinking ERα Degradation as the Driver for SERD Efficacy
(2h)
oveporexton (TAK-861)
(4d)
Regioselective Synthesis of N-Aryl Pyrazoles Stemming from an Academic-Industrial Collaboration
(5d)
Labiotech.EU
Seven biotechs driving progress in Duchenne muscular dystrophy
(4h)
We asked 19 biotech leaders what breaks their deals. It wasn’t the science.
(1d)
Top biotech deals in July 2026
(4d)
Bio IT World
A Brain Orchestra … Playing at a Range of Unsynchronized Tempos
(12h)
New CEO for PacBio, Updated Chemistry for Vega System
(4d)
‘Reproductive Resilience Hypothesis’ Highlights the Ovary as a Discovery Source in Longevity Research
(5d)
GEN News
Bispecific Antibody Purification’s Complexity Problem and How to Fix It
(58m)
Indiana Emerges as a Leading U.S. Biopharma Hub
(4h)
How South Carolina Became the Southeast’s Fastest Growing Biotech Hub
(4h)
Cure Today
Text a Survivor: Sally Kalksma on Life With Multiple Myeloma
(2h)
Weekly App Check-Ins Eased Fatigue in Metastatic Breast Cancer
(4h)
Divesiran Eliminates Need for Phlebotomy in 88% of Patients With Polycythemia Vera
(21h)
Contract Pharma
CPHI Unveils Pharma Sustainability Summit
(2h)
ILiAD Appoints Former GSK Exec as Chief Business Officer
(3h)
Altasciences Expands Bioanalytical Labs in North America
(4h)
Pharma Times
Lexeo wins FDA RMAT status for LX2020
(8h)
EHP Awards 2027 open for entries
(8h)
NICE backs new blood cancer regimens
(1d)
Medcity News
From Friction to Fix: Measuring What’s Breaking Payer-Provider Trust
(4h)
Which Health Tech Companies Are Getting Customer Experience Right?
(5h)
How CMS Is Tackling ‘Coverage Purgatory’ for Medical Devices
(18h)
Chemical & Engineering News
Chemistry advances when disciplines connect
(5h)
Periodic Graphics: Caterpillars vs. plants: A chemical battle
(21h)
Memory Lane: Laboratory science before safety data sheets
(22h)
The Pharma Letter
CellProthera inks MoU for ProtheraCytes distribution in Japan
(3h)
Long-acting therapies continue to gain momentum in HIV
(5h)
FDA rejects ITM’s ¹⁷⁷Lu-edotreotide filing
(6h)
Targeted Oncology
Study Finds Genomic Profiling Turnaround Time Improves, but Delays Persist
(22m)
Myeloma Physicians Consider Approaches to Subcutaneous Therapy
(1h)
Ravi Salgia, MD, PhD, Discusses the ADAPT-Funded IMMUNO-BIOMAP Trial in NSCLC
(4h)
MedWatch
Eli Lilly faces criticism for Danish new campaign
(4h)
Novo Nordisk launches once-weekly insulin treatment in the US
(5h)
Eli Lilly maintains plans for production facilities in Germany despite billion-dollar cuts
(8h)
In The Pipeline
So How Is AI Drug Discovery Doing, Really?
(19h)
This Is Why We Run Trials, Unfortunately
(4d)
Put Your Money Down, They Say
(4d)
Pharmaphorum
England close to eliminating hep C thanks to treatment drive
(7h)
Trump order upturns federal childhood vaccines policy
(7h)
UK is first European country to approve Lilly's Foundayo
(9h)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
HIT Consultant
Why Digital Health Founders Should Stop Worrying if They Are “AI Enough”
(13h)
From “Maybe” to Baltic Gods: The Stories Behind Virus Names
(13h)
Kyndryl to Acquire Healthcare IT Leaders: Scaling AI Modernization Across Hospitals and Payors
(18h)
Insights: Pink Sheet
New EU Tool Helps Drug Developers Check If They Need A Joint Clinical Assessment
(1h)
UCB Gets Scottish Funding For Zilbrysq, But England’s NICE Not Convinced
(1h)
UK MHRA Sets Diversity Goal For ‘Western Authority Dominated’ PIC/S Pharmacovigilance Group
(3h)
BioXconomy
DOJ adopts targeted approach to mergers
(2h)
RNA and ethical quandaries in Spider-Man: Brand New Day
(2h)
CMS, HRSA target 340B with new payment, rebate rules
(3h)
BioCentury
FIH urgency in the U.S. Plus: federated learning, biotech IPOs — a BioCentury podcast
(16h)
Jazz expands neuro reach with rare epilepsy takeout: Deals Report
(18h)
Auchincloss bill would embed trials in routine care, speed FIH starts
(18h)
SCRIP
Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
(8h)
Stock Watch: Why Investors Sold Sanofi Despite The Headline Beat
(8h)
Tenax Sees A Path Forward For TNX-103 Despite Phase III LEVEL Miss
(20h)